Tag - RGNX

Executive Moves

Healthcare investor veteran Greg Ciongoli joins REGENXBIO’s board

REGENXBIO (NASDAQ: RGNX) has announced the appointment of Greg Ciongoli to its board of directors, effective August 25, 2026. Mr. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and...

August 26, 2026

Developments

REGENXBIO completes dosing in study of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has completed dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (DMD). According to REGENXBIO, this milestone positions the...

June 24, 2026

Developments

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...

March 11, 2026

Tag - RGNX

Healthcare investor veteran Greg Ciongoli joins REGENXBIO’s board

REGENXBIO completes dosing in study of RGX-202 in DMD

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

Subscribe